Geneveve Treatment
vaginal rejuvenation

Geneveve Vaginal Rejuvenation Treatment

Geneveve is a non-surgical vaginal rejuvenation treatment to tighten the vagina and increase sensation and sexual satisfaction. Patients also report it can help with urinary incontinence. The Geneveve procedure applies radio frequency energy to the vagina, stimulating the body to produce more collagen, while cooling the surface tissue to avoid discomfort. One 30-minute treatment session is usually recommended. Women agree the treatment works because:

  • The treatment is designed for improving women’s health and overall quality of life
  • It is comfortable, discreet and a single-session
  • They can FEEL the difference

The Geneveve treatment uses clinically-proven cryogen-cooled monopolar radiofrequency (CMRF) to uniformly deliver gentle volumetric heating while cooling delicate surface tissue. This unique technology stimulates the body’s natural collagen formation process. The Geneveve treatment is a comfortable, single-session, 30-minute treatment performed by a trained healthcare professional in an outpatient setting. Currently used in many countries around the world, the Geneveve treatment has benefitted thousands of women and improved their health and quality of life.

 

Leading vaginal plastic surgeon Christine Hamori discusses the difference between Viveve and ThermiVa and what results she has seen from her patients. A graduate of Tulane University School of Medicine (MD), Dr. Hamori completed her surgical residency at Boston University, where she was chosen chief resident. She then completed a plastic surgery residency at University of Pennsylvania. She is the head MD at Christine Hamori Cosmetic Surgery in Boston, MA

Christine Hamori

MD, Christine Hamori Cosmetic Surgery

The Only Treatment Tested in a Large-scale, Multicenter Sham-controlled Study

The importance of validated clinical evidence for the Geneveve treatment cannot be overstated because often with women’s health and wellness there is a lack of serious attention to scientific rigor.

“We as physicians have a duty of care to define outcomes, demand properly designed and controlled trials and insist that results are published in reputable, peer reviewed medical journals. In my opinion, anything less diminishes our obligation as physicians to our patients.”
– Bruce Allan, PhD, MD Founder & Director, Allan Centre, Calgary Alberta Canada, Principal Investigator, Viveve Clinical Trials, Medical Consultant to Viveve, Inc.

Establishing a benchmark for energy-based device companies, Viveve undertook and successfully completed a multicenter, blinded, randomized, sham controlled study of an elective vaginal procedure to assess the effect the treatment had on women suffering from the changes their bodies undergo after vaginal childbirth.

The Viveve I study demonstrated:

  • There were NO serious adverse events in patients treated with the active treatment
  • Improvement of arousal and/or orgasm was statistically significant as self-reported by 9 out of 10 patients (Data on file and publication pending)

Further, two previous pilot clinical trials conducted by Viveve in the U.S. and Japan, showed sustained tightening at 12 months. (Data on file)